|Awarded On||February 21, 2018|
|Title||Elucidating the Epigenetic and Metabolic Vulnerabilities of Myeloproliferative Neoplasms|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Jian Xu|
Myeloproliferative neoplasms (MPNs) are progressive blood cancers that can strike anyone at any age, and for which there is no cure. MPNs are characterized by alterations of multiple signaling and epigenetic pathways, yet the molecular processes controlling MPN progression from chronic to leukemic transformation remain unknown. This is a major impediment for developing target-based therapies to selectively eliminate cancer stem cells to prevent disease progression and/or relapse. The challenge is twofold: 1) to identify the genetic complexity of MPN pathophysiology, and 2) to control the progression of MPNs from indolent to life-threatening stages. Inactivation of EZH2, the epigenetic enzyme...